Kiniksa Pharmaceuticals, Ltd. — Q1 2020 Form 10-Q
Reporting period: Three months ended March 31, 2020. Financial statements are unaudited; amounts below are in U.S. dollars. Kiniksa is a clinical-stage biopharmaceutical company and reported no product revenue.
Financial performance and position
| Metric | Q1 2020 | Q1 2019 / comparison |
|---|---|---|
| Product revenue | None | None |
| Research and development expense | $20.9 million | $59.3 million |
| General and administrative expense | $8.5 million | $8.4 million |
| Operating loss | $29.4 million | $67.6 million |
| Interest income | $0.8 million | $1.8 million |
| Income tax benefit | $2.2 million | $0.02 million |
| Net loss | $26.4 million | $65.8 million |
| Basic and diluted loss per share | $0.48 | $1.27 |
| Net cash used in operating activities | $31.8 million | $63.3 million |
- R&D spending fell $38.4 million year over year, primarily because Q1 2019 included an $18.0 million Primatope acquisition charge and a $10.0 million Biogen milestone. Spending also declined across individual programs.
- At March 31, cash and cash equivalents were $106.3 million and short-term investments were $97.9 million, totaling $204.2 million, versus $233.4 million at December 31, 2019. Cash and cash equivalents rose during the quarter largely as short-term investments matured; investing cash flow was a net $88.8 million inflow.
- Total assets were $226.1 million, total liabilities $20.3 million, and shareholders’ equity $205.8 million at March 31. The filing reports no borrowings; liabilities included operating lease obligations.
- Margins are not meaningful because the company had no product revenue. Accumulated deficit was $382.5 million.
Business developments, outlook and risks
- Pipeline: Rilonacept’s pivotal Phase 3 RHAPSODY trial in recurrent pericarditis and mavrilimumab’s Phase 2 trial in giant cell arteritis had completed enrollment. Management expected top-line results from both in the second half of 2020. Rilonacept had FDA Breakthrough Therapy designation for recurrent pericarditis.
- Management reported that the vixarelimab Phase 2a prurigo nodularis trial met its primary efficacy endpoint. Data from its exploratory chronic-pruritus trial were expected in the first half of 2020. KPL-404 Phase 1 data were expected in the second half of 2020.
- Kiniksa was engaging with the FDA and preparing for a potential mavrilimumab development program for COVID-19 pneumonia and hyperinflammation. A CRO temporarily paused new-patient enrollment and dosing in the KPL-404 Phase 1 trial because of COVID-19; management did not then expect a timeline impact, but noted a prolonged pause could affect timing and data breadth.
- COVID-19 could disrupt trials, enrollment, manufacturing, suppliers, shipping, regulatory review and commercial preparation, and could constrain access to capital. The company said operations had been partially affected, with office access restricted and most staff working remotely.
- Management expected continuing operating losses and significant R&D and commercialization-preparation costs. It stated that cash, cash equivalents and short-term investments should fund operating expenses and capital needs for at least 12 months from issuance of the financial statements; longer-term viability depends on raising additional capital. The estimate depends on assumptions and could prove inaccurate.
- Other notable items: Kiniksa terminated its Novo Nordisk license for KPL-045 in January 2020. CFO Chris Heberlig departed in March; a replacement search had begun. No material legal proceedings were reported. Manufacturing commitments totaled $1.5 million.
Important facts for investors to verify
- Whether RHAPSODY and the mavrilimumab GCA trial delivered the anticipated second-half 2020 results, and what the final data showed.
- Whether COVID-19 affected enrollment, trial execution, manufacturing or regulatory timelines beyond management’s expectations, particularly for KPL-404.
- Cash burn against the stated 12-month runway, including how clinical-trial and potential commercialization costs evolve and whether additional financing is needed.
- Whether vixarelimab’s reported Phase 2a result is confirmed in full data and whether further development is supported.
- Potential dilution and voting-control implications: the filing describes a multi-class share structure and significant voting influence by management and certain investors.